These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 16673282

  • 1. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
    Finazzi G.
    Semin Thromb Hemost; 2006 Apr; 32(3):276-82. PubMed ID: 16673282
    [Abstract] [Full Text] [Related]

  • 2. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [Abstract] [Full Text] [Related]

  • 3. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [Abstract] [Full Text] [Related]

  • 4. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Cancer J; 2007 Jun; 13(6):372-6. PubMed ID: 18032974
    [Abstract] [Full Text] [Related]

  • 5. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
    Finazzi G, low-dose aspirin in polycythemia (ECLAP).
    Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
    [Abstract] [Full Text] [Related]

  • 6. The treatment of polycythaemia vera: an update in the JAK2 era.
    Finazzi G, Barbui T.
    Intern Emerg Med; 2007 Mar; 2(1):13-8. PubMed ID: 17551678
    [Abstract] [Full Text] [Related]

  • 7. Evidence-based management of polycythemia vera.
    Barbui T, Finazzi G.
    Best Pract Res Clin Haematol; 2006 Mar; 19(3):483-93. PubMed ID: 16781485
    [Abstract] [Full Text] [Related]

  • 8. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
    Landolfi R, Marchioli R.
    Semin Thromb Hemost; 1997 Mar; 23(5):473-8. PubMed ID: 9387206
    [Abstract] [Full Text] [Related]

  • 9. How I treat patients with polycythemia vera.
    Finazzi G, Barbui T.
    Blood; 2007 Jun 15; 109(12):5104-11. PubMed ID: 17264301
    [Abstract] [Full Text] [Related]

  • 10. Diagnosis and therapy of polycythemia vera.
    Lengfelder E, Merx K, Hehlmann R.
    Semin Thromb Hemost; 2006 Apr 15; 32(3):267-75. PubMed ID: 16673281
    [Abstract] [Full Text] [Related]

  • 11. Front-line therapy in polycythemia vera and essential thrombocythemia.
    Barbui T, Finazzi MC, Finazzi G.
    Blood Rev; 2012 Sep 15; 26(5):205-11. PubMed ID: 22784966
    [Abstract] [Full Text] [Related]

  • 12. Treatment of polycythemia vera.
    Barbui T, Finazzi G.
    Haematologica; 1998 Feb 15; 83(2):143-9. PubMed ID: 9549926
    [Abstract] [Full Text] [Related]

  • 13. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar 15; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 14. Risk factors and prevention of vascular complications in polycythemia vera.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 1997 Mar 15; 23(5):455-61. PubMed ID: 9387204
    [Abstract] [Full Text] [Related]

  • 15. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May 15; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 16. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
    Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T.
    J Clin Oncol; 2005 Apr 01; 23(10):2224-32. PubMed ID: 15710945
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S.
    Thromb Haemost; 1997 Jul 01; 78(1):622-6. PubMed ID: 9198227
    [Abstract] [Full Text] [Related]

  • 18. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2013 Jun 01; 88(6):507-16. PubMed ID: 23695894
    [Abstract] [Full Text] [Related]

  • 19. Erythromelalgia and vascular complications in polycythemia vera.
    Michiels JJ.
    Semin Thromb Hemost; 1997 Jun 01; 23(5):441-54. PubMed ID: 9387203
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA.
    Semin Oncol; 2002 Jun 01; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.